The prerandomization LDL cholesterol concentration (after a run-in period on pitavastatin 1 mg/d) was 88 mg/dL. Those randomly assigned to the 4 mg/d pitavastatin achieved an LDL cholesterol level 14.7 mg/dL lower than those continuing on the 1 mg/d dose. Those taking the high-dose in comparison with low-dose pitavastatin had a statistically significant 19% lower risk of having a primary end point (4.3% versus 5.4%). There were also significant reductions in all-cause death (19%), myocardial infarction (43%), and clinically indicated coronary revascularization (14%). These results were independent of the baseline level of LDL cholesterol. Rates of serious adverse events were low in both groups. 7 There were no significant effects of pitavastatin dose on either ischemic or hemorrhagic stroke, although there was a numeric 46% increase in hemorrhagic stroke (P=0.11). The absence of an effect on ischemic stroke (83 versus 84) may have reflected the relatively small number of events and should not be overinterpreted. Similarly, numeric (not significant) increase in hemorrhagic stroke in the higher-dose pitavastatin group (43 versus 30) should be viewed with caution because of the low number of events.
These results of the REAL-CAD trial are generally consistent with those in trials conducted in white populations. The results provide robust support for the use of high-dose statins in high-risk people in Asia.
One finding in the REAL-CAD trial warrants particular emphasis. The group receiving pitavastatin at a dose of 4 mg/d had a significantly lower risk of all-cause death than was observed in the group taking 1 mg/d. It should be noted, however, that deaths from cardiovascular causes in REAL-CAD are a minority, and not all causes of death were described in this article.
In REAL-CAD there was a 19% reduction in all-cause death (207 versus 260) in those taking 4 versus 1 mg of pitavastatin per day (P=0.03). This contrasts with the results in trials of more versus less LDL cholesterol lowering conducted in white populations (Table) . The TNT trial (Treatment to New Targets) compared the effects of atorvastatin given at a dose of either 80 mg/d or 10 mg/d. The concentration of LDL cholesterol was 24 mg/ dL lower in those taking the higher dose of atorvastatin, and the risk of having a major cardiovascular event was 22% lower (P<0.001). But there was no significant effect on all-cause death. 3 In the IDEAL trial (Initiating Dialysis Early and Late), the effect of atorvastatin at a dose of 80 mg/d was compared with the effects of simvastatin at a dose of 20 or 40 mg/d. The LDL cholesterol level was 23 mg/dL lower in those taking atorvastatin and, although the primary end point was not significantly reduced, there was a 13% significant reduction in major cardiovascular events 8 (P=0.02). But again, there was no significant effect on all-cause death. The PROVE-IT trial (Pravastatin or Atorvastatin Evaluation and Infection Therapy), conducted in a population who had had a recent acute coronary syndrome, compared effects of 80 mg/d atorvastatin with 40 mg/d pravastatin. The LDL cholesterol level was 33 mg/dL lower in those taking atorvastatin, and there was a 16% (P=0.005) reduction in the primary end point. Although there was a numeric 28% reduction in all-cause death, this was not statistically significant (P=0.07). 4 The IMPROVE-IT trial (Improved Reduction of Outcomes: Vytorin Efficacy CHD indicates coronary heart disease; LDL, low-density lipoprotein; LDL-C, low-density lipoprotein cholesterol; and MI, myocardial infarction. *Primary end point in the trials. TNT: death from CHD, nonfatal non-procedure-related myocardial infarction, resuscitation after cardiac arrest, or fatal or nonfatal stroke; IDEAL: major coronary event, defined as coronary death, confirmed nonfatal acute MI, or cardiac arrest with resuscitation; PROVE-IT: death from any cause, myocardial infarction, documented unstable angina requiring rehospitalization, revascularization (performed at least 30 days after randomization), and stroke; IMPROVE-IT: cardiovascular death, nonfatal myocardial infarction, unstable angina requiring rehospitalization, coronary revascularization (≥30 days after randomization), or nonfatal stroke; FOURIER: cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization; and REAL-CAD: cardiovascular death, nonfatal myocardial infarction, nonfatal ischemic stroke, or unstable angina requiring emergency hospitalization. International) compared effects of simvastatin alone with those of simvastatin plus ezetimibe. In comparison with the simvastatin-only group, those taking simvastatin plus ezetimibe had an LDL cholesterol level 16 mg/dL lower and a 6.4% (P=0.016) lower risk of having a major cardiovascular event, but there was no significant effect on all-cause death. 5 The FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) compared the effects of statin alone with those of statin plus the PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor, evolocumab. In those taking evolocumab, the LDL cholesterol was 62 mg/dL lower and the risk of having a major cardiovascular event was reduced by 15% (P<0.001). Again, as in the other trials in whites, there was no significant effect on all-cause death. 6 It is uncertain why all-cause death was significantly reduced in REAL-CAD but not in the trials conducted in white populations. REAL-CAD did not have the longest follow-up (3.9 years versus 2-6 years in the trials in whites). REAL-CAD did not have the greatest difference in LDL cholesterol levels (15 mg/dL versus 16-62 mg/dL in the trials in whites). Nor were there more deaths in REAL-CAD (467 versus 240-2446 deaths in the trials in whites). It is possible that the explanation lies in the population studied, with Japanese people having a response to high-dose statins that differs from the response in whites. It is possible that pitavastatin has unknown protective properties that are not shared by other LDL-lowering therapies. It is also possible that other therapies with the potential to reduce death are used differently in high-risk Japanese and white populations.
Regardless of the explanation, the findings in RE-AL-CAD are robust and add major strength to a case for using high-dose statins in high-risk patients, in Japanese and other Asian populations. The results of REAL-CAD have implications beyond Asia and add strong support to current recommendations in white populations for the use of high doses of an effective statin in those at high risk of having an ASCVD event.
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